Abstract: The invention is in the field of molecular diagnosis of medical diseases and their treatment. More in particular, it provides methods and means for detecting hypertension, more in particular essential primary hypertension, even more in particular NOX5-dependent hypertension. The invention also provides methods for the treatment of hypertension, in particular essential primary hypertension, more in particular NOX5-dependent hypertension. The invention also provides theragnostics, wherein therapy is combined with diagnosis, more in particular wherein the level of NOX5 is determined in a sample from a subject and wherein the subject is treated with NOX5 inhibitors or compounds that decrease the levels of NOX5 if the NOX5 levels are above a certain threshold value.

Abstract: The invention relates to a pharmaceutical composition comprising one or more stimulators of soluble guanylate cyclase (sGC), or a combination of at least one stimulator of sGC and at least one activator of sGC, for use in a method of treatment of a disease and/or a disorder that is/are associated with a deficiency of cyclic 3?,5?-guanosine monophosphate in the patient to be treated. The invention also relates to a therapeutic combination comprising a first unit dose comprising an sGC stimulator and a second unit dose comprising an sGC activator. The invention also relates to a therapeutic combination comprising a first unit dose comprising a first sGC stimulator and a second unit dose comprising a second sGC stimulator, for use in a method for the treatment of a disease and/or a disorder that is/are associated with a deficiency of cyclic 3?,5?-guanosine monophosphate in the patient to be treated.

Abstract: The invention is in the field of molecular diagnosis of medical diseases and their treatment. More in particular, it provides methods and means for detecting hypertension, more in particular essential primary hypertension, even more in particular NOX5-dependent hypertension. The invention also provides methods for the treatment of hypertension, in particular essential primary hypertension, more in particular NOX5-dependent hypertension. The invention also provides theragnostics, wherein therapy is combined with diagnosis, more in particular wherein the level of NOX5 is determined in a sample from a subject and wherein the subject is treated with NOX5 inhibitors or compounds that decrease the levels of NOX5 if the NOX5 levels are above a certain threshold value.

Abstract: The invention is in the field of molecular diagnosis of medical diseases and their treatment. More in particular, it provides methods and means for detecting hypertension, more in particular essential primary hypertension, even more in particular NOX5-dependent hypertension. The invention also provides methods for the treatment of hypertension, in particular essential primary hypertension, more in particular NOX5-dependent hypertension. The invention also provides theragnostics, wherein therapy is combined with diagnosis, more in particular wherein the level of NOX5 is determined in a sample from a subject and wherein the subject is treated with NOX5 inhibitors or compounds that decrease the levels of NOX5 if the NOX5 levels are above a certain threshold value.